Press and media
Press releases
More regular updates and key information, updates and news can be found through our tweets
CellCentric presents early haem clinical data at ASH
CellCentric to present haem clinical data at ASH
CellCentric strengthens leadership team
Latest tweets from @CellCentric
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.
Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.
Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.
Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.